KN vs MLAB Stock Comparison: AI Score, Valuation, Performance and Upside
KN (Knowles Corporation) and MLAB (Mesa Labs) are both specialty technology component companies in distinct niches — Knowles is the global MEMS microphone market leader serving smartphones, hearing aids, and voice-interface devices with semiconductor-precision acoustic technology, while Mesa Labs is a quality compliance measurement and calibration company serving pharmaceutical, medical, and industrial regulated industry requirements through calibration services, biological indicators, and data integrity solutions.
KN vs MLAB is MEMS microphone technology leader with consumer electronics and hearing health exposure (Knowles's global microphone manufacturing leadership, hearing aid acoustic heritage, and voice interface proliferation tailwind — smartphone cyclicality, Infineon/AAC competition, and Apple concentration risk) versus niche laboratory calibration and sterilization compliance provider with recurring consumable demand (Mesa Labs's regulatory mandate-driven calibration services, biological indicator consumables, and acquisition-driven diversification — integration complexity, clinical genomics normalization, and small-cap liquidity).
KN and MLAB are closely matched — they split the tracked metrics evenly. KN has delivered stronger 1-year price return (+142.36% vs +3.05%), though MLAB trades at the lower forward P/E (7.75x vs 26.56x). Analyst consensus implies meaningfully more upside for MLAB (+17.77%) than for KN (-12.38%).
- →Want semiconductor component exposure through MEMS microphone technology leadership with multi-decade manufacturing expertise serving smartphones, hearing aids, and voice-interface devices
- →Value Knowles's dual exposure to cyclical consumer electronics (smartphone microphones) and more stable hearing health demographics (hearing aid acoustic components for aging global population)
- →Believe voice interface proliferation (smart speakers, smartphone voice assistants, hearables) increases microphone count per device and creates new high-value audio applications for Knowles's technology
- →Want quality compliance measurement exposure through the recurring demand of pharmaceutical and hospital calibration and sterilization validation requirements that cannot be deferred under FDA and USP regulations
- →Value Mesa Labs's biological indicator consumables as a recurring revenue model where every sterilization cycle uses disposable biological test products — creating predictable non-discretionary demand
- →Accept acquisition integration complexity for Mesa Labs's strategy of consolidating niche quality compliance measurement businesses that individually are too small for larger industrial companies to pursue
| Metric | KN | MLAB |
|---|---|---|
| AI score | 41.0 | 25.1 |
| AI rank | #995 | #2859 |
| Latest close | $41.37 | $95.10 |
| 1M return | +21.43% | -4.59% |
| 6M return | +88.99% | +19.60% |
| 1Y return | +142.36% | +3.05% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | KN | MLAB |
|---|---|---|
| 1Y ago | $24.24K (+142.4%) started 2025-06-18 | $10.38K (+3.8%) started 2025-06-18 |
| 5Y ago | $21.77K (+117.7%) started 2021-06-18 | $3.85K (-61.5%) started 2021-06-18 |
| 10Y ago | $27.13K (+171.3%) started 2016-06-20 | $8.45K (-15.5%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
| Metric | KN | MLAB |
|---|---|---|
| Market cap | $3.54B | $525.42M |
| Trailing P/E | 58.27 | 78.60 |
| Forward P/E | 26.56 | 7.75 |
| Price/Sales | 5.76 | 2.11 |
| EV/Revenue | 5.94 | 2.67 |
| Analyst target | $36.25 | $112.00 |
| Target upside | -12.38% | +17.77% |
| Metric | KN | MLAB |
|---|---|---|
| Revenue growth | 15.80% | 2.60% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | +7.47% | +12.80% |
| Operating margin | N/A | N/A |
| Profit margin | 9.10% | 2.69% |
| ROIC proxy | 8.15% | 3.88% |
| Return on equity | 8.15% | 3.88% |
| Dividend yield | 0.00% | 0.67% |
| Beta | 1.61 | 0.93 |
| Debt/equity | 19.44 | 90.65 |
| Current ratio | 3.27 | 1.72 |
| Quick ratio | 1.65 | 1.17 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | KN | MLAB |
|---|---|---|---|
| 1Y | Growth | +142.36% | +3.05% |
| CAGR | +142.50% | +3.05% | |
| Sharpe ratio | 2.60 | 0.30 | |
| Max drawdown | 15.32% | 44.45% | |
| Max daily drop | 5.34% | 24.92% | |
| Max wkly drop | 8.95% | 25.19% | |
| 5Y | Growth | +117.74% | -62.52% |
| CAGR | +16.84% | -17.82% | |
| Sharpe ratio | 0.50 | -0.24 | |
| Max drawdown | 49.55% | 82.43% | |
| Max daily drop | 14.69% | 24.92% | |
| Max wkly drop | 18.03% | 25.19% | |
| 10Y | Growth | +171.28% | -19.13% |
| CAGR | +10.50% | -2.10% | |
| Sharpe ratio | 0.33 | 0.07 | |
| Max drawdown | 49.55% | 82.43% | |
| Max daily drop | 19.56% | 25.72% | |
| Max wkly drop | 22.74% | 26.36% |
| Category | KN | MLAB |
|---|---|---|
| Company | Knowles Corporation | Mesa Labs, Inc. |
| Sector | Technology - MEMS Microphones and Audio Acoustics Components | Healthcare/Industrials - Laboratory Measurement, Calibration, and Quality Compliance |
| Industry | N/A | N/A |
| Core business | Knowles Corporation is the world's largest manufacturer of MEMS (microelectromechanical systems) microphones — tiny silicon-based microphones used in smartphones, hearables (AirPods, wireless earbuds), hearing aids, smart speakers, and IoT devices. Knowles's miniaturized MEMS microphone technology converts sound waves to electrical signals with high sensitivity and low power consumption in an extremely small package suitable for modern consumer electronics. Knowles also provides precision audio processing ICs, balanced armature speakers for hearing aids and in-ear monitors, and acoustic solutions. Knowles serves Apple, Samsung, and other major smartphone OEMs, as well as hearing aid companies (Sonova, WS Audiology, Starkey). Knowles has been a market leader in hearing aid acoustic components for over 60 years. | Mesa Labs provides critical measurement, calibration, testing, and data integrity solutions for regulated industries including pharmaceuticals, medical devices, food and beverage, and industrial applications. Mesa's business segments include: Calibration Solutions (providing calibration of test and measurement equipment for pharmaceutical and industrial quality systems — validating that temperature sensors, pressure gauges, pipettes, and other instruments measure accurately); Sterilization and Disinfection Control (biological indicators for validating sterilization processes in hospitals and medical device manufacturers — small biological test indicators that verify sterilization cycles killed all bacteria); Clinical Genomics (Bios International, acquired, providing controls for clinical PCR testing); and Data Integrity (Validatek/Temprime — providing data logging and environmental monitoring for GDP/GMP compliance in pharmaceutical cold chain). Mesa Labs has grown primarily through acquisitions of niche measurement and compliance businesses. |
| Investor focus | Investors track Knowles's revenue by market (consumer electronics vs. hearing health vs. precision devices), MEMS microphone market share, content per device (number of microphones per smartphone increasing with voice assistant features), and margin improvement from product mix shift toward higher-value audio solutions. | Investors track Mesa Labs's organic revenue growth across segments, EBITDA margin, acquisition integration progress, and the recurring nature of calibration and compliance consumable revenue. |
- →MEMS microphone market leadership with multi-decade manufacturing expertise creates a significant barrier to entry — producing high-quality MEMS microphones requires precision semiconductor fabrication expertise; Knowles has refined its process over decades; new entrants face long development timelines to reach comparable performance
- →Hearing health market provides stable, non-cyclical revenue from an aging global population with increasing hearing loss prevalence — hearing aid demand grows with demographics; hearing aid acoustic components are long-term relationships with hearing device OEMs
- →Voice interface proliferation (Amazon Echo, Apple HomePod, Google Nest, and smartphone voice assistants) increases microphone count per device and creates new use cases for high-quality MEMS microphones
- →Calibration and sterilization validation are regulatory requirements — pharmaceutical manufacturers and hospitals must validate their equipment and sterilization processes under FDA/USP/cGMP regulations; this regulatory mandate creates non-discretionary, recurring demand for Mesa's calibration services and biological indicators
- →Biological indicators are consumables with recurring demand — each sterilization cycle in a hospital or medical device company requires using a biological indicator (a disposable product with live bacterial spores); this consumable model provides recurring revenue independent of capital equipment cycles
- →Niche market leadership in specialized compliance niches reduces competition — Mesa Labs's calibration solutions and biological indicator businesses serve specialized regulatory compliance needs that mainstream industrial companies find unattractive due to the regulatory complexity and small market sizes
- →Smartphone market cyclicality creates revenue volatility — MEMS microphone volumes are highly tied to smartphone production; when smartphone sales decline (as in 2022-2023), Knowles's consumer revenue falls accordingly
- →Competition from Infineon, AAC Technologies, and other MEMS microphone manufacturers — the MEMS microphone market has multiple capable competitors; Knowles maintains leadership through performance advantage but faces pricing pressure in commodity microphone tiers
- →Apple customer concentration risk — Apple is likely Knowles's largest customer; any design win loss or Apple production volume decline has significant impact on Knowles's financials
- →Acquisition-driven growth strategy requires effective integration — Mesa has grown through multiple acquisitions; integrating acquired businesses (systems, culture, products) while sustaining organic growth is operationally complex
- →Clinical genomics segment integration and diagnostics market cyclicality — Mesa's clinical genomics controls business serves the PCR testing market, which experienced COVID-driven surge then normalization; managing a diagnostics business requires different expertise than calibration
- →Small-cap liquidity risk — Mesa Labs's market capitalization makes it a smaller, less liquid stock that institutional investors may overlook; liquidity constraints affect bid-ask spreads and the stock's ability to reflect fair value
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.